期刊
JOURNAL OF BIOMEDICAL SCIENCE
卷 24, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s12929-017-0329-9
关键词
PD-1; PD-L1; Cancer immunotherapy; Immune checkpoint
资金
- Grants-in-Aid for Scientific Research [16H05477, 17K19591] Funding Source: KAKEN
Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据